Evidence map›Paper›PMID 32661544›Full record

ArticleJournal of materials chemistry. B2020

Photoinduced reconfiguration to control the protein-binding affinity of azobenzene-cyclized peptides.

Kevin Day, John D Schneible, Ashlyn T Young, Vladimir A Pozdin, George Van Den Driessche, Lewis A Gaffney, Raphael Prodromou, Donald O Freytes, Denis Fourches, Michael Daniele and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of materials chemistry. B, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Kevin DayDepartment of Chemical and Biomolecular Engineering, North Carolina State University, 911 Partners Way, Raleigh, North Carolina, USA. smenega@ncsu.edu.
John D SchneibleDepartment of Chemical and Biomolecular Engineering, North Carolina State University, 911 Partners Way, Raleigh, North Carolina, USA. smenega@ncsu.edu.ORCID http://orcid.org/0000-0003-2974-6298
Ashlyn T YoungJoint Department of Biomedical Engineering, North Carolina State University - University of North Carolina Chapel Hill, North Carolina, USA. mdaniel6@ncsu.edu.ORCID http://orcid.org/0000-0001-9288-8585
Vladimir A PozdinJoint Department of Biomedical Engineering, North Carolina State University - University of North Carolina Chapel Hill, North Carolina, USA. mdaniel6@ncsu.edu.
George Van Den DriesscheDepartment of Chemistry, North Carolina State University, 2700 Stinson Dr, Raleigh, NC 27607, USA.
Lewis A GaffneyJoint Department of Biomedical Engineering, North Carolina State University - University of North Carolina Chapel Hill, North Carolina, USA. mdaniel6@ncsu.edu.
Raphael ProdromouDepartment of Chemical and Biomolecular Engineering, North Carolina State University, 911 Partners Way, Raleigh, North Carolina, USA. smenega@ncsu.edu.
Donald O FreytesJoint Department of Biomedical Engineering, North Carolina State University - University of North Carolina Chapel Hill, North Carolina, USA. mdaniel6@ncsu.edu.
Denis FourchesDepartment of Chemistry, North Carolina State University, 2700 Stinson Dr, Raleigh, NC 27607, USA.
Michael DanieleJoint Department of Biomedical Engineering, North Carolina State University - University of North Carolina Chapel Hill, North Carolina, USA. mdaniel6@ncsu.edu.ORCID http://orcid.org/0000-0002-2016-4091
Stefano MenegattiDepartment of Chemical and Biomolecular Engineering, North Carolina State University, 911 Partners Way, Raleigh, North Carolina, USA. smenega@ncsu.edu.
North Carolina State University · USUniversity of North Carolina at Chapel Hill · US

Funding

Pre-doctoral Training Program in Integrative Vascular BiologyT32HL069768 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Christopher P. Mack · 2002 to 2026
$9.7M
NHLBI NIH HHS T32 HL069768
6 · The paper itself

Abstract

The impact of next-generation biorecognition elements (ligands) will be determined by the ability to remotely control their binding activity for a target biomolecule in complex environments. Compared to conventional mechanisms for regulating binding affinity (pH, ionic strength, or chaotropic agents), light provides higher accuracy and rapidity, and is particularly suited for labile targets. In this study, we demonstrate a general method to develop azobenzene-cyclized peptide ligands with light-controlled affinity for target proteins. Light triggers a cis/trans isomerization of the azobenzene, which results in a major structural rearrangement of the cyclic peptide from a non-binding to a binding configuration. Critical to this goal are the ability to achieve efficient photo-isomerization under low light dosage and the temporal stability of both cis and trans isomers. We demonstrated our method by designing photo-switchable peptides targeting vascular cell adhesion marker 1 (VCAM1), a cell marker implicated in stem cell function. Starting from a known VCAM1-binding linear peptide, an ensemble of azobenzene-cyclized variants with selective light-controlled binding were identified by combining in silico design with experimental characterization via spectroscopy and surface plasmon resonance. Variant cycloAZOB[G-VHAKQHRN-K] featured rapid, light-controlled binding of VCAM1 (KD,trans/KD,cis ∼ 130). Biotin-cycloAZOB[G-VHAKQHRN-K] was utilized to label brain microvascular endothelial cells (BMECs), showing co-localization with anti-VCAM1 antibodies in cis configuration and negligible binding in trans configuration.

Indexed as

Photochemical ProcessesAmino Acid SequenceAzo CompoundsHydrogen-Ion ConcentrationIsomerismOsmolar ConcentrationPeptides, CyclicazobenzeneAzo CompoundsPeptides, Cyclic

Identifiers

PMID32661544
PMCPMC7945681
OpenAlexW3033653744

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.